Piramal Pharma Solutions To Develop Sofpironium Bromide API At Riverview Facility With Botanix

On May 18, 2026, Piramal Pharma Solutions announced a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited. The collaboration will focus on drug substance development and validation of Sofpironium Bromide API, strengthening PPS’s role as a global CDMO partner.

Partnership Details

Under the agreement, PPS will initiate development and validation services for Sofpironium Bromide API at its Riverview, Michigan facility. Following successful regulatory approval, PPS and Botanix may extend validation to PPS’s Aurora, Canada facility, creating a dual-source supply chain strategy for long-term flexibility and security.

Strategic Importance

Sofpironium Bromide is the active pharmaceutical ingredient in Sofdra®, the first and only FDA-approved new chemical entity for primary axillary hyperhidrosis. This condition, characterized by excessive underarm sweating, has lacked effective treatments until Sofdra’s approval. PPS’s involvement ensures robust production and supply chain resilience for this novel therapy.

Industry Context

The partnership highlights the growing importance of contract development and manufacturing organizations (CDMOs) in supporting innovative therapies. PPS’s Riverview and Aurora facilities, equipped with advanced systems and regulatory expertise, provide redundancy and supply chain continuity, ensuring uninterrupted patient access even amid global uncertainties.

Partnership Highlights

•⁠  ⁠PPS to initiate development and validation of Sofpironium Bromide API at Riverview, Michigan

•⁠  ⁠Collaboration with Botanix Pharmaceuticals to support Sofdra® drug substance development

•⁠  ⁠Sofdra® is FDA-approved for treating primary axillary hyperhidrosis

•⁠  ⁠Potential dual-site validation at Riverview (US) and Aurora (Canada) facilities

•⁠  ⁠Strategy enhances supply chain flexibility, resilience, and cost efficiency

•⁠  ⁠PPS reinforces its role as a trusted CDMO partner in specialty pharmaceuticals

Sources: PR Newswire, Yahoo Finance, Botanix Pharmaceuticals ASX Announcement